LynxBio is is developing technologies enabling the prediction of clinical treatment response for multiple myeloma (MM) and other blood cancer patients.
MicroC3™ is an assay that rapidly analyzes the therapeutic response of patients' own tumor cells with their own non-tumor cells, creating a representative model of a patient's own cancer.
Microfluidic ex vivo assay unique to each patient and able to be performed for all patients
Results within 3 days of standard of care biopsy
Not tied to a single biomarker and can be developed as companion diagnostic to any blood cancer therapy
Early small retrospective studies identified all patients (n=17) as either clinically responsive (7) or non-responsive (10) to a commonly used MM drug
Small prospective clinical trial ongoing and currently enrolling patients
Pak et al. MicroC3: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integrative Biology, 2015, 7, 643 – 654. Featured cover page article.